Pozen (Nasdaq: POZN) is expanding the markets for its migraine drug MT 400 through a licensing deal with a division of Johnson & Johnson.

Cilag GmbH International gained rights to MT 400 for Brazil, Columbia, Ecuador and Peru. Cilag is responsible for the manufacturing, development and commercialization of MT 400 in those countries.

Pozen will receive an upfront payment of an undisclosed amount.

GlaxoSmithKline (NYSE: GSK) licenses the drug in a different dosage for sale in the US under the name Treximet.

Get the latest news alerts: Follow WRAL Tech Wire at Twitter.